October 31, 2019

To whom it may concern,

Company: Japan Lifeline Co., Ltd.
Representative: Keisuke Suzuki, President and CEO
(Code: 7575 TSE 1st Section)
Contact person: Shogo Takahashi, Senior Vice President,
Corporate Administration Department
(TEL. +81-3-6711-5200)

Announcement regarding the First Clinical Case of In-house EP Catheters in North America

Japan Lifeline Co., Ltd. ("JLL") announced today that Baylis Medical Company, Inc. ("Baylis Medical") received approval from the U.S. Food and Drug Administration (FDA) in June of this year for JLL's proprietary EP (electrophysiology) catheter "EPstar", and that its first clinical use in the North American market took place in September of 2019.

Baylis Medical is the developer and manufacturer of the NRG Transseptal Needle, a radiofrequency transseptal needle, for which JLL has an exclusive distributorship in Japan. Since its launch in 2013, JLL has been successfully distributing this product all over Japan as a unique product in the market and has built a collaborative relationship with Baylis Medical. Since last year, both companies have given thought not only to domestic sales but also to new business. As a result, JLL has been preparing to begin sales in North America utilizing the knockdown system. This is a system, in which JLL exports semi-finished products to be completed on-site by Baylis Medical.

EPstar is an EP catheter developed and manufactured by JLL. It was launched in 2002 for the use of examination and diagnosis of arrhythmias. JLL has achieved the top-class market share in this product category in Japan through the constant development and improvement of products that reflect the needs of healthcare professionals. The export for North America at this time is specifically focused on the 2Fr EP catheter and the 6Fr EP guiding catheter, which are distinct products with few competitors. These two catheters, however, are amongst a vast EP product lineup carried by JLL.

Both catheters are specifically made to be placed in the coronary sinus of the heart. By utilizing a 6Fr EP guiding catheter with a lumen and a very small 2Fr EP catheter which goes into the lumen, the catheters can provide access to the distal part of the coronary sinus, an area that has been difficult to reach with conventional EP catheters. JLL anticipates that these products will provide a better option for more accurate diagnoses of arrhythmias in the targeted market.

The first case in North America, the world's largest market, is a very meaningful step for JLL as exporting its in-house products overseas has been an important medium-to-long-term challenge. Although the contribution to the business performance is expected to be limited at this time, as the full release scheduled for around early 2020 is solely for the 2Fr EP catheter and the 6Fr EP guiding catheter, JLL is determined to further strengthen its collaboration with Baylis Medical.

END

About Baylis Medical

Baylis Medical is a leader in the development and commercialization of innovative medical devices in the field of cardiology, with a focus on left-heart access. Headquartered in Canada, and with offices world-wide, their clinical solutions have been Improving the Lives of People Around the World for over 30 years. For more information, visit www.baylismedical.com.